Magdalena Yesil - 05 Jun 2025 Form 4 Insider Report for SoFi Technologies, Inc. (SOFI)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
12 Jun 2025, 17:57:27 UTC
Prior SEC filing
03 Jun 2025
Next SEC filing
11 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Deanna M. Smith, Attorney-in-Fact

Key filing fact

Magdalena Yesil filed Form 4 for SoFi Technologies, Inc. (SOFI) on 12 Jun 2025.

Key facts

  • This page summarizes Magdalena Yesil's Form 4 filing for SoFi Technologies, Inc. (SOFI).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 12 Jun 2025, 17:57.

Change

  • Previous filing in this sequence was filed on 03 Jun 2025.
  • Current net transaction value: -$2,469,800.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001225481 Primary reporting owner

YESIL MAGDALENA

Relationship
Director
Address
C/O SOFI TECHNOLOGIES, INC., 234 1ST STREET, SAN FRANCISCO
Signature
/s/ Deanna M. Smith, Attorney-in-Fact
Signature date
12 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SOFI transaction

Common Stock

Sale

Transaction value
$1,215,760
Shares
-87,140
Change %
-19%
Price
$13.95
Shares after
376,398
Date
05 Jun 2025
Ownership
By Spouse
Footnotes
F1
SOFI transaction

Common Stock

Sale

Transaction value
$1,254,040
Shares
-87,140
Change %
-23%
Price
$14.39
Shares after
289,258
Date
10 Jun 2025
Ownership
By Spouse
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SOFI transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares
+18,388
Change %
Price
Shares after
18,388
Date
10 Jun 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
18,388
Exercise price
Footnotes
F3, F4
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The reported transactions were executed in multiple trades. The sale price of $13.9518 reported in Column 4 is the weighted average sale price for the 87,140 shares sold by the Reporting Person within a range of $13.95 to $13.97 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the price range noted above.

Footnote F2

The reported transactions were executed in multiple trades. The sale price of $14.3911 reported in Column 4 is the weighted average sale price for the 87,140 shares sold by the Reporting Person within a range of $14.39 to $14.40 per share. The Reporting Person hereby undertakes to provide to the Staff of the SEC, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the price range noted above.

Footnote F3

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration.

Footnote F4

Reflects a grant of RSUs to the Reporting Person, a director of the Issuer, which will vest at the earlier of (i) the next annual shareholder meeting of the Issuer after June 9, 2025 (the "Vesting Commencement Date") or (ii) the 12 month anniversary of the Vesting Commencement Date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .